Show simple item record

dc.contributor.authorZhang Rui-yanzh_CN
dc.contributor.authorZhang Qizh_CN
dc.contributor.authorZhu Jin-zhouzh_CN
dc.contributor.authorChen Liang-longzh_CN
dc.contributor.authorZhang Chen-yunzh_CN
dc.contributor.authorZhou Xu-chenzh_CN
dc.contributor.authorYuan Yongzh_CN
dc.contributor.authorZhong Zhi-xiongzh_CN
dc.contributor.authorLi Langzh_CN
dc.contributor.authorQiu Jianzh_CN
dc.contributor.authorWang Weizh_CN
dc.contributor.authorChen Xi-mingzh_CN
dc.contributor.authorYang Zhi-jianzh_CN
dc.contributor.authorYan Jin-chuanzh_CN
dc.contributor.authorChen Shao-liangzh_CN
dc.contributor.authorHou Yu-qingzh_CN
dc.contributor.authorWu Yan-qingzh_CN
dc.contributor.authorLuo Hai-mingzh_CN
dc.contributor.authorQiu Jian-pizh_CN
dc.contributor.author王燕zh_CN
dc.date.accessioned2015-07-22T07:02:07Z
dc.date.available2015-07-22T07:02:07Z
dc.date.issued2011-11-05zh_CN
dc.identifier.citationCHINESE MEDICAL JOURNAL, 2011,124(21):3521-3526zh_CN
dc.identifier.otherWOS:000297658200017zh_CN
dc.identifier.urihttps://dspace.xmu.edu.cn/handle/2288/90057
dc.description.abstractBackground Polymer coating on coronary stents induces vascular inflammatory response, reduces re-endothelialization, and affects long-term outcome after percutaneous coronary intervention (PCI). The SERY-1 registry aimed to determine whether a novel polymer-free paclitaxel-eluting microporous Yinyi stent could improve 1-year outcome after index procedure in real-world clinical practice. Methods Clinical and angiographic data and follow-up outcome were collected in 1045 patients who underwent PCI with implantation of >= 1 Yinyi stents between June 2008 and August 2009 at 27 medical centers. The primary endpoint was the cumulative rate cif composite major adverse cardiac events (MACE) and the secondary endpoint was the incidence of stent thrombosis at 1 year. Results Overall, 1376 lesions were treated successfully with 1713 Yinyi stents, and 1019 (98.7%) patients received dual antiplatelet therapy for at least 12 months. During 1-year follow-up, 8 patients (0.78%) had cardiac death, 6 (0.58%) suffered non-fatal myocardial infarction, and 46 (4.46%) underwent repeat PCI due to recurrence of angina, resulting in 1-year MACE-free survival of 94.09%. Stent thrombosis occurred in 10 (0.97%) patients, and the rate of Academic Research Consortium (ARC) definite or probable stent thrombosis was 0.78%. Conclusions Polymer-free paclitaxel-eluting microporous Yinyi stent is effective and safe for interventional treatment of coronary artery disease in real-world clinical practice, without recourse to carrier polymer. Potential long-term clinical advantages of this stent deserve further investigation. Chin Med J 2011;124(21):3521-3526zh_CN
dc.language.isoen_USzh_CN
dc.publisherCHINESE MED J-PEKINGzh_CN
dc.source.urihttp://dx.doi.org/10.3760/cma.j.issn.0366-6999.2011.21.016zh_CN
dc.subjectCORONARY-ARTERY-DISEASEzh_CN
dc.subjectLATE LUMEN LOSSzh_CN
dc.subjectRANDOMIZED-TRIALzh_CN
dc.subjectDRUGzh_CN
dc.subjectTHROMBOSISzh_CN
dc.subjectOUTCOMESzh_CN
dc.subjectHYPERSENSITIVITYzh_CN
dc.subjectMECHANISMSzh_CN
dc.subjectRAPAMYCINzh_CN
dc.subjectCHINESEzh_CN
dc.titleSafety and efficacy of polymer-free paclitaxel-eluting microporous stent in real-world practice: 1-year follow-up of the SERY-I registryzh_CN
dc.typeArticlezh_CN


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record